Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients toward higher-priced insulin in order to reap ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...